Evropska unija - švedščina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

abbvie ab - foskarbidopa; foslevodopa - infusionsvätska, lösning - 240 mg/ml + 12 mg/ml - foskarbidopa 12 mg aktiv substans; foslevodopa 240 mg aktiv substans

Evropska unija - švedščina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - migrän störningar - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Evropska unija - švedščina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - sevofluran - inhalationsånga, vätska - sevofluran 1 ml aktiv substans

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

abbvie ab - epinastinhydroklorid - Ögondroppar, lösning - 0,5 mg/ml - epinastinhydroklorid 0,5 mg aktiv substans; bensalkoniumklorid hjälpämne - epinastin

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

abbvie ab - parikalcitol - kapsel, mjuk - 4 mikrogram - glycerol hjälpämne; etanol, vattenfri hjälpämne; butylhydroxitoluen hjälpämne; parikalcitol 4 mikrog aktiv substans; propylenglykol hjälpämne - parikalcitol

Evropska unija - švedščina - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - immunsuppressiva - se produktinformationsdokumentet.

Evropska unija - švedščina - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - lopinavir, ritonavir - hiv-infektioner - antivirals for systemic use, protease inhibitors - kaletra är indicerat i kombination med andra antiretrovirala läkemedel för behandling av hiv-1-infekterade vuxna, ungdomar och barn i åldern 14 dagar och äldre. valet av kaletra för att behandla proteashämmare erfarna hiv-1 infekterade patienter bör baseras på individuella viral resistens testning och behandling historia av patienter.

Evropska unija - švedščina - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ritonavir - hiv-infektioner - antivirala medel för systemisk användning - ritonavir är indicerat i kombination med andra antiretrovirala medel för behandling av hiv-1-infekterade patienter (vuxna och barn som är två år och äldre).